Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy

Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy

Anlotinib is a new multitarget tyrosine kinase inhibitor for tumor angiogenesis, and its monotherapy exhibits a decent clinical efficacy. However, the process of combining Anlotinib and immune checkpoint therapy to achieve optimal antitumor effects while limiting side effects remains unclear. In thi...

Full description

Bibliographic Details
Main Authors: Peng Fan, Huiping Qiang, Zhenhua Liu, Qi Zhao, Ying Wang, Tingkun Liu, Xuan Wang, Tianqing Chu, Yuhui Huang, Wei Xu, Songbing Qin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
Effective low-dose
Anlotinib
Anti-PD1 therapy
CD8+ T cell
Long-term vascular normalization
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.937924/full

Similar Items

Similar Items